• IL-2, Human Recombinant: Reading EV Inflammation

  2026-10-08

  Explore how IL-2, human recombinant can help frame immune-response questions raised by Porphyromonas gingivalis extracellular vesicles. This evidence-focused analysis separates what the latest study demonstrates from what recombinant IL-2 could conceptually contribute to future periodontal–vascular research.

• Estradiol: Receptor Signaling and Organ Protection

  2026-10-08

  Estradiol, also called 17 beta-estradiol, is an endogenous estrogen that acts through ERα and ERβ to regulate transcription and cell signaling. Recent human and mouse evidence links lower estradiol with adverse cardiometabolic markers and identifies receptor–autophagy signaling as a mechanistic research theme, but the findings do not establish clinical treatment efficacy.

• Sulfo-NHS-LC-Biotin Product Overview

  2026-10-07

  Sulfo-NHS-LC-Biotin, also known as sulfosuccinimidyl-6-(biotinamido) hexanoate, is listed by APExBIO as a water-soluble reagent for covalent biotin labeling of accessible primary amines. No matched research paper was provided, so performance, assay compatibility, and application-specific effectiveness cannot be independently assessed.

• TRIM21–ERK1/2 Signaling in Pituitary Adenomas

  2026-10-07

  Liu and colleagues identify TRIM21 as a regulator of pituitary adenoma proliferation and treatment resistance, linking its E3-ligase activity to ERK1/2 ubiquitination and phosphorylation. The study also reports Quisinostat as a screening hit that lowers TRIM21 protein levels, while emphasizing that the findings remain preclinical and require validation across broader models.

• Quinolone–Coumarin Hybrids Against T. gondii

  2026-10-06

  A 2024 Acta Parasitologica study evaluated 12 quinolone–coumarin hybrids derived from fluoroquinolone and novobiocin-related scaffolds against Toxoplasma gondii in vitro. QC1, QC3, QC6, and novobiocin showed the most favorable combined activity and host-cell selectivity, although the findings remain an early lead-generation signal rather than evidence of clinical efficacy.

• PTK6, Autophagy, and Uveal Melanoma

  2026-10-06

  The 2023 Cell Death and Disease study identifies a PTK6–SOCS3–mTOR relationship that links autophagy suppression with uveal melanoma growth, migration, and invasion. Its main contribution is a mechanistic model in which PTK6 promotes tumor-associated phenotypes partly by regulating SOCS3 and mTOR phosphorylation, while the evidence remains primarily cellular and requires further validation.

• V5 Epitope Tag Peptide: Reading the Signal

  2026-10-05

  The V5 Epitope Tag Peptide is more than a molecular label: it is a defined antibody-recognition element whose value depends on epitope accessibility, antibody kinetics, and assay context. This evidence-focused guide connects the GKPIPNPLLGLDST peptide with modern single-molecule antibody screening while clarifying what the data can—and cannot—support.

• OPP and B-Cell Protein Synthesis: Evidence Review

  2026-10-05

  O-propargyl-puromycin (OPP) offers a conceptual readout of nascent protein synthesis that can help interpret how Pcbp1, mitochondrial integrity, and antibody production are connected in B cells. This overview compares the strengths and limitations of OPP-based protein synthesis measurement with the mechanistic and organism-level evidence reported by Zhu et al.

• Dantrolene Sodium Salt: Evidence and Limits

  2026-10-04

  Dantrolene sodium salt is best understood as a calcium-signaling research compound with a supplier-described ryanodine receptor antagonist profile. A recent CRISPR drug-repurposing study identified pharmacological modulators of DNA double-strand-break repair, but the supplied evidence does not establish dantrolene as a validated regulator of NHEJ, MMEJ, or HDR. This overview separates reported findings from plausible but unconfirmed connections.

• Rucaparib: Evidence, Principles, and Limits

  2026-10-03

  A source-grounded overview of Rucaparib and AG-014699, covering PARP biology, evidence quality, interpretation, model-specific scope, and the limits of current supplied sources.

• BFH772 (VEGFR2 inhibitor): Workflow Guide

  2026-10-02

  BFH772 is a selective small-molecule VEGFR2 inhibitor for controlled studies of VEGFR2 signaling and angiogenesis, particularly biochemical, cellular, and tumor angiogenesis workflows. Its water insolubility and defined kinase selectivity make it unsuitable for water-based formulations, broad-spectrum kinase screening, or direct clinical efficacy conclusions.

• Sulfo-NHS-Biotin for SEC-seq Workflows

  2026-10-01

  Sulfo-NHS-Biotin adds a surface-phenotype layer to secretion-focused single-cell workflows without replacing the secretion or transcriptome readouts. This guide explains how to combine amine-reactive labeling with nanovial-based SEC-seq, affinity capture, and immunoprecipitation while protecting cell viability and assay specificity.

• Adamtsl3, MMP9, and Perineuronal Net Plasticity

  2026-10-01

  The 2026 Molecular Psychiatry study identifies Adamtsl3 as a cell-autonomous regulator of perineuronal-net integrity in parvalbumin-positive interneurons. Its genetic and pharmacological experiments connect Adamtsl3 loss with elevated MMP9 activity, oxidative stress, impaired Otx2 uptake, and the return of juvenile-like cortical plasticity in adult mice.

• BV6 and the Cell-Death Decision: From IAPs to Translation

  2026-09-30

  BV6 is a Smac mimetic and selective IAP antagonist that helps translational researchers interrogate apoptosis, therapy resistance, and cell-death pathway context. This article connects BV6 evidence in cancer and endometriosis models with the RIPK3–MLKL insights reported in Orientia tsutsugamushi infection biology, while distinguishing established findings from forward-looking experimental opportunities.

• CD38 CAR Binders: Structure-Guided Affinity Tuning

  2026-09-30

  Cheng et al. define how the CD38 CAR binders RP02 and 028 engage different antigen surfaces and differently regulate CD38 enzymatic activity. Structural mapping, alanine scanning, and CAR-T testing show that attenuating 028 affinity can reduce fratricide while preserving antitumor cytotoxicity, providing a rational framework for CD38-directed receptor design.

7996 records 1/534 page Next 12345 下5页 Last page